HRP20010741A2 - Use of osanetant in the production of medicaments used to treat mood disorders - Google Patents
Use of osanetant in the production of medicaments used to treat mood disorders Download PDFInfo
- Publication number
- HRP20010741A2 HRP20010741A2 HR20010741A HRP20010741A HRP20010741A2 HR P20010741 A2 HRP20010741 A2 HR P20010741A2 HR 20010741 A HR20010741 A HR 20010741A HR P20010741 A HRP20010741 A HR P20010741A HR P20010741 A2 HRP20010741 A2 HR P20010741A2
- Authority
- HR
- Croatia
- Prior art keywords
- osanetant
- treatment
- intended
- use according
- disorders
- Prior art date
Links
- DZOJBGLFWINFBF-UMSFTDKQSA-N osanetant Chemical compound C([C@](C1)(CCCN2CCC(CC2)(N(C(C)=O)C)C=2C=CC=CC=2)C=2C=C(Cl)C(Cl)=CC=2)CCN1C(=O)C1=CC=CC=C1 DZOJBGLFWINFBF-UMSFTDKQSA-N 0.000 title claims description 11
- 229950009875 osanetant Drugs 0.000 title claims description 11
- 208000019022 Mood disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 208000020401 Depressive disease Diseases 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000003542 behavioural effect Effects 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 208000024732 dysthymic disease Diseases 0.000 claims description 2
- 229940127554 medical product Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 101001125071 Homo sapiens Neuromedin-K receptor Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 101150006061 neur gene Proteins 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Description
Bit izuma
Osanetant je Nedozvoljeno međunarodno ime (Interanational Non-proprietary Name, INN) (R)(+)N[(3(1benzoil3(3,4-diklorfenil)piperidin-3-il)propil)-4-fenilpiperidin-4-il]-N-metilacetamida, koji ima slijedeću formulu
[image] .
Ovaj spoj i njegove farmaceutski prihnatljive soli opisani su u Evropskoj patentnoj prijavi, objavljenoj kao EP 673 928.
Ovi spojevi opisani su kao selektivni antagonisti ljudskog NK3 receptora, koji su korisni u tretmanu poremećaja povezanih s disfunkcijom dopaminergičkog i noradrenergičkog sustava.
Sada je uočeno da su osanetant i njegove farmaceuski prihvatljive soli korisni u tretmanu poremećaja ponašanja, osobito u tretmanu depresije. Pod depresijom se, osobito, misli na teže depresivne poremećaje, blaže depresivne poremećaje, distimiju, depresivne poremećaje povezane s anksioznošću i depresivne poremećaje povezane s bipoplarnim poremećajima.
Djelovanja osanetanta na teže depresivne poremećaje istraživano je kod pacijenata od 18-65 godina starosti. Pacijentima je 6 tjedana davan osanetant (200 mg dnevno).
Poboljšavanje depresivnog sindroma mjereno je od značajnog smanjenja u rezultatima na Hamilton-ovoj skali (J. Neur. Neurosurg. Psych., 23, 56-62, 1960.) i bilježenjem dojmova kliničara i pacijentovih ukupnih dojmova.
Prema tome, cilj ovog izuma je upotreba osanetanta i njegovih farmaceutski prihvatljivih soli u pripravljanju medicinskih proizvoda koje se upotrebljava u tretmanu poremećaja ponašanja, osobito u tretmanu depresije.
Osanetant i njegove farmaceutski prihvatljive soli dobiva se prema Evropskoj patentnoj prijavi, objavljenoj kao EP 673 928; slično tome, farmaceutske pripravke može se prirediti kao što je opisano u istoj patentnoj prijavi.
U farmaceutske pripravke iz ovog izuma namijenjene oralnoj, sublingvalnoj, supkutanoj, intramuskularnoj, intravenskoj, transdermalnoj, lokalnoj ili rektalnoj primjeni, aktivni sastojak, bilo sam ili u kombinaciji s drugim aktivnim sastojkom, može se primijeniti u obliku jedinice za primjenu, u kombinaciji s konvencionalnim farmaceutskim ekscipijensima, kako kod životinja, tako i kod ljudi. Odgovarajući oblici jedinica za primjenu uključuju oblik za primjenu oralnim putem, poput tableta, kapsula, praškova, granula i otopina ili suspenzija za oralnu primjenu, oblike za sublingvalnu i bukalnu primjenu, aerosole, implantate, oblike za supkutanu, transdermalnu, intramuskularnu, intravensku, intranazalnu i rektalnu primjenu.
Dnevna doza spoja prema ovom izumu kreće se od 0,05-5 mg/kg, po mogućnosti od 1-2,5 mg/kg, još bolje od 22,5 mg/kg i primjenjuje se jednom ili nekoliko puta dnevno. Spojeve se općenito priređuje kao jedinice doziranja od 2,5-500 mg, po mogućnosti od 50-250 mg, još bolje od 100-250 mg aktivnog sastojka po jedinici doziranja, radi jednokratne primjene, dvaput ili nekoliko puta, prema potrebi. Iako su ova doziranja primjeri tipičnih situacija, u posebnim slučajevima mogu biti pogodne više ili niže doze, a takva doziranja također su dio ovog izuma. Prema uobičajenoj praksi, pogodno doziranje za svakog pacijenta određuje liječnik, prema postupku primjene, dobi, tjelesnoj težini i odgovoru navedenog pacijenta.
Prema ovom izumu, poželjni su oralni oblici primjene.
Spojeve prema ovom izumu može se primijeniti usporedo s drugim aktivnim sastojkom, osobitoantidepresivom, poput npr. litijeve soli, tricikličkog antidepresiva, inhibitora monoaminoksidaze ili inhibitora povratnog unosa serotonina.
Ovaj izum također se odnosi na postupak tretmana poremećaja ponašanja, osobito postupak tretmana depresije, primjenom odgovarajuće doze osanetanta ili jedne od njegovih farmaceutski prihvatljivih soli.
PRIMJERI
Primjer 1
Kapsula koja sadrži 250 mg osanetanta
[image]
*otpareno tijekom sušenja nakon mokre granulacije. ;Primjer 2 ;Kapsula koja sadrži 100 mg osanetanta ;[image] ;*otpareno tijekom sušenja nakon mokre granulacije.
Claims (7)
1. Upotreba osanetanta i njegovih farmaceutski prihvatljivih soli, naznačena time što je namijenjena pripravljanju medicinskih proizvoda korisnih u tretmanu poremećaja ponašanja.
2. Upotreba prema zahtjevu 1, naznačena time što je namijenjena tretmanu depresije.
3. Upotreba prema zahtjevu 2, naznačena time što je namijenjena tretmanu težih depresivnih poremećaja.
4. Upotreba prema zahtjevu 2, naznačena time što je namijenjena tretmanu distimije.
5. Upotreba prema zahtjevu 2, naznačena time što je namijenjena tretmanu blažih depresivnih poremećaja.
6. Upotreba prema zahtjevu 2, naznačena time što je namijenjena tretmanu depresivnih poremećaja popraćenih anksioznošću.
7. Upotreba prema zahtjevu 2, naznačena time što je namijenjena tretmanu depresivnih poremećaja popraćenih bipolarnim poremećajima.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9904699A FR2792199B3 (fr) | 1999-04-13 | 1999-04-13 | Utilisation de l'osanetant pour la preparation de medicaments utiles dans le traitement des troubles de l'humeur |
| PCT/FR2000/000924 WO2000061125A2 (fr) | 1999-04-13 | 2000-04-11 | L'osanetant dans le traitement des troubles de l'humeur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20010741A2 true HRP20010741A2 (en) | 2002-10-31 |
Family
ID=9544412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20010741A HRP20010741A2 (en) | 1999-04-13 | 2001-10-12 | Use of osanetant in the production of medicaments used to treat mood disorders |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6420388B1 (hr) |
| EP (1) | EP1175215A2 (hr) |
| JP (1) | JP2002541190A (hr) |
| KR (1) | KR20010105418A (hr) |
| CN (1) | CN1354662A (hr) |
| AR (1) | AR023452A1 (hr) |
| AU (1) | AU3971600A (hr) |
| BR (1) | BR0009704A (hr) |
| CA (1) | CA2369638A1 (hr) |
| CZ (1) | CZ20013645A3 (hr) |
| EE (1) | EE200100527A (hr) |
| FR (1) | FR2792199B3 (hr) |
| HR (1) | HRP20010741A2 (hr) |
| HU (1) | HUP0200655A3 (hr) |
| ID (1) | ID30458A (hr) |
| IS (1) | IS6098A (hr) |
| MX (1) | MXPA01010340A (hr) |
| NO (1) | NO20014953L (hr) |
| PE (1) | PE20010032A1 (hr) |
| PL (1) | PL351554A1 (hr) |
| SK (1) | SK14552001A3 (hr) |
| TR (1) | TR200102930T2 (hr) |
| WO (1) | WO2000061125A2 (hr) |
| ZA (1) | ZA200108289B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001095904A1 (en) * | 2000-06-12 | 2001-12-20 | University Of Rochester | Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist |
| WO2005061544A2 (en) * | 2003-12-22 | 2005-07-07 | Glaxo Group Limited | Nogo-a neutralising immunoglobulins for treatment of neurological diseases |
| JP2007530591A (ja) * | 2004-03-25 | 2007-11-01 | スミスクライン・ビーチャム・コーポレイション | 双極性障害を治療するための、ｎｋ３アンタゴニストの使用 |
| EP1867717A4 (en) * | 2005-03-15 | 2008-08-20 | Sumitomo Chemical Co | METHOD FOR REDUCE SYMPTOM CAUSED BY MUTUAL DISORDER |
| JP2006320201A (ja) * | 2005-05-17 | 2006-11-30 | Sumitomo Chemical Co Ltd | 気分障害又は関連障害による疾患症状を改善させる方法 |
| GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
| EP3915560A1 (en) | 2014-06-25 | 2021-12-01 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2719311B1 (fr) | 1994-03-18 | 1998-06-26 | Sanofi Sa | Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic. |
| FR2729954B1 (fr) * | 1995-01-30 | 1997-08-01 | Sanofi Sa | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| FR2738819B1 (fr) * | 1995-09-14 | 1997-12-05 | Sanofi Sa | Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant |
| AU4176997A (en) | 1996-09-16 | 1998-04-02 | Warner-Lambert Company | 3-alkyl-3-phenyl-piperidines |
-
1999
- 1999-04-13 FR FR9904699A patent/FR2792199B3/fr not_active Expired - Fee Related
-
2000
- 2000-04-11 ID IDW00200102144A patent/ID30458A/id unknown
- 2000-04-11 JP JP2000610458A patent/JP2002541190A/ja not_active Withdrawn
- 2000-04-11 MX MXPA01010340A patent/MXPA01010340A/es not_active Application Discontinuation
- 2000-04-11 PL PL00351554A patent/PL351554A1/xx not_active Application Discontinuation
- 2000-04-11 EE EEP200100527A patent/EE200100527A/xx unknown
- 2000-04-11 TR TR2001/02930T patent/TR200102930T2/xx unknown
- 2000-04-11 CN CN00806091A patent/CN1354662A/zh active Pending
- 2000-04-11 CZ CZ20013645A patent/CZ20013645A3/cs unknown
- 2000-04-11 BR BR0009704-7A patent/BR0009704A/pt not_active Application Discontinuation
- 2000-04-11 EP EP00918941A patent/EP1175215A2/fr not_active Withdrawn
- 2000-04-11 KR KR1020017012990A patent/KR20010105418A/ko not_active Application Discontinuation
- 2000-04-11 CA CA002369638A patent/CA2369638A1/en not_active Abandoned
- 2000-04-11 SK SK1455-2001A patent/SK14552001A3/sk unknown
- 2000-04-11 HU HU0200655A patent/HUP0200655A3/hu unknown
- 2000-04-11 WO PCT/FR2000/000924 patent/WO2000061125A2/fr not_active Application Discontinuation
- 2000-04-11 US US09/958,266 patent/US6420388B1/en not_active Expired - Fee Related
- 2000-04-11 AU AU39716/00A patent/AU3971600A/en not_active Abandoned
- 2000-04-12 AR ARP000101670A patent/AR023452A1/es unknown
- 2000-04-13 PE PE2000000343A patent/PE20010032A1/es not_active Application Discontinuation
-
2001
- 2001-09-28 IS IS6098A patent/IS6098A/is unknown
- 2001-10-09 ZA ZA200108289A patent/ZA200108289B/xx unknown
- 2001-10-11 NO NO20014953A patent/NO20014953L/no not_active Application Discontinuation
- 2001-10-12 HR HR20010741A patent/HRP20010741A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1175215A2 (fr) | 2002-01-30 |
| PL351554A1 (en) | 2003-05-05 |
| TR200102930T2 (tr) | 2002-04-22 |
| CZ20013645A3 (cs) | 2002-01-16 |
| NO20014953L (no) | 2001-12-11 |
| NO20014953D0 (no) | 2001-10-11 |
| US6420388B1 (en) | 2002-07-16 |
| AU3971600A (en) | 2000-11-14 |
| FR2792199A1 (fr) | 2000-10-20 |
| EE200100527A (et) | 2002-12-16 |
| IS6098A (is) | 2001-09-28 |
| ZA200108289B (en) | 2002-12-24 |
| SK14552001A3 (sk) | 2002-02-05 |
| AR023452A1 (es) | 2002-09-04 |
| CA2369638A1 (en) | 2000-10-19 |
| PE20010032A1 (es) | 2001-04-11 |
| HUP0200655A2 (hu) | 2002-07-29 |
| JP2002541190A (ja) | 2002-12-03 |
| KR20010105418A (ko) | 2001-11-28 |
| FR2792199B3 (fr) | 2001-05-18 |
| BR0009704A (pt) | 2002-01-08 |
| CN1354662A (zh) | 2002-06-19 |
| HUP0200655A3 (en) | 2002-11-28 |
| MXPA01010340A (es) | 2002-05-06 |
| ID30458A (id) | 2001-12-06 |
| WO2000061125A3 (fr) | 2001-04-19 |
| WO2000061125A2 (fr) | 2000-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6444665B1 (en) | Method for treating pain | |
| HU225534B1 (en) | Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors | |
| EP1154795B1 (en) | Means for treating and diagnosing restless legs syndrome | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| AU1217697A (en) | Method of treating and diagnosing sleep disordered breathing and means for carrying out the method | |
| KR20010032009A (ko) | 수면성 무호흡의 치료에 미타자핀을 사용하는 방법 | |
| ZA200600159B (en) | Novel solid pharmaceutical composition comprising amisulpride | |
| HRP20010741A2 (en) | Use of osanetant in the production of medicaments used to treat mood disorders | |
| RU2261098C2 (ru) | Перорально распадающаяся композиция, содержащая миртазапин | |
| US4719212A (en) | Therapeutic agent for memory disturbance | |
| JP5386477B2 (ja) | 脊髄損傷を治療するための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシドピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用 | |
| WO1998024411A2 (en) | Method for oral administration of buspirone | |
| EA010868B1 (ru) | Применение производных бицикло[2.2.1]гептана для приготовления нейропротекторных фармацевтических композиций | |
| EP1901726A2 (en) | Composition for treatment of psychosis | |
| TWI439269B (zh) | ４－環丙基甲氧基－ｎ－（３，５－二氯－１－氧離子基吡啶－４－基）－５－（甲氧基）吡啶－２－甲醯胺於製備用於治療與帕金森氏病有關之運動障礙症的藥物之用途 | |
| TWI417090B (zh) | 黃酮類化合物於治療伴有感覺運動門控缺損的精神異常疾病的用途 | |
| JP5386476B2 (ja) | 頭蓋外傷の治療のための４−シクロプロピルメトキシ−ｎ−（３，５−ジクロロ−１−オキシド−４−ピリジン−４−イル）−５−（メトキシ）ピリジン−２−カルボキサミドの使用 | |
| EA003584B1 (ru) | Способ стимуляции отказа от курения или его снижения или предупреждения возобновления курения и применение пароксетина или его фармацевтически приемлемых солей или сольватов для получения лекарственного средства | |
| CN116920101A (zh) | 一种用于重度抑郁症治疗的新的药物组合 | |
| KR20220110259A (ko) | 통증 질환에 사용하기 위한 미르타자핀 및 티자니딘 배합물 | |
| KR20010099647A (ko) | 신규 조성물 | |
| WO2002056868A2 (en) | Method for treating stress or tension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20020411 Year of fee payment: 3 |
|
| A1OB | Publication of a patent application | ||
| OBST | Application withdrawn |